Pharmacophore-Based Discovery of Licoisoflavanone as a Dual CXCR4/CXCR7 Inhibitor for Coronary Artery Disease: Integration of Traditional Chinese Medicine and Modern Computational Approaches
Authors:
- Faisal AliFAFaisal Ali
- Shabana BibiSBShabana Bibi
- Mustapha BelaidiMBMustapha Belaidi
- Saleh M. BufarwaSBSaleh M. Bufarwa
- Anum AshrafAAAnum Ashraf
- Huma FatimaHFHuma Fatima
- Ghadeer M. AlbadraniGAGhadeer M. Albadrani
- Muath Q. Al-GhadiMuath Q. Al-Ghadi
- Rawan AltalhiRARawan Altalhi
- Mohamed M. Abdel-DaimMohamed M. Abdel-Daim
- 22 October 2025
- journal article
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 25 (11) , 1935-1954
Abstract
Coronary artery disease (CAD) is still a primary cause of death worldwide, prompting the development of innovative therapeutic strategies. In this work, 149 possible candidates were identified by creating a ligand-based pharmacophore model of traditional Chinese herbal medicines using FDA-approved CAD drugs as templates. Licoisoflavanone (MOL004885) was identified as the most promising dual inhibitor by subsequent molecular docking against the chemokine receptors CXCR4 and CXCR7. It showed significant binding affinities of −10.1 kcal/mol and −9.5 kcal/mol, respectively. Licoisoflavanone’s stability inside the binding sites of both receptors was validated by molecular dynamics simulations conducted over 200 ns, and MMGBSA analysis revealed a particularly advantageous interaction with CXCR4. Stereoisomeric analysis of the [ ]- and [ ]-forms of Licoisoflavanone revealed comparable stability and interaction patterns with both receptors. Pharmacokinetic predictions demonstrated nonmutagenic properties and good oral absorption. Additionally, the chemical stability and reactivity balance of the molecule were confirmed using density functional theory (DFT) calculations. These findings further support the dual-targeting potential of both enantiomers. All of these results point to Licoisoflavanone as a good candidate for additional research and development as a novel therapeutic drug that targets CXCR4/CXCR7 in the treatment of CAD.Keywords
Funding Information
- Princess Nourah Bint Abdulrahman University (PNURSP2025R30)
- Female Center for Scientific and Medical Colleges, King Saud University (RSPD2025R811)
This publication has 62 references indexed in Scilit:
- Noncovalent interactions between benzochalcogenadiazoles and nitrogen basesJournal of Molecular Modeling, 2022
- A Conceptual Density Functional Theoretic View of Chemical Binding2022
- Optimizing Bedaquiline for cardiotoxicity by structure based virtual screening, DFT analysis and molecular dynamic simulation studies to identify selective MDR-TB inhibitorsIn Silico Pharmacology, 2021
- UCSF ChimeraX: Structure visualization for researchers, educators, and developersProtein Science, 2020
- Small-Molecule Library Screening by Docking with PyRx2014
- Review of Pharmacological Effects of Glycyrrhiza sp. and its Bioactive CompoundsPhytotherapy Research, 2008
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- Drug Design Strategies for Targeting G-Protein-Coupled ReceptorsChemBioChem, 2002
- The role of antiplatelet therapy in acute coronary syndromes and for secondary prevention following a myocardial infarctionProgress in Cardiovascular Diseases, 1993
- Quantenchemie: Horizons of Quantum Chemistry. Proceedings of the Third International Congress of Quantum Chemistry, Kyoto, Japan 1979. Hrsg. von K. Fukui/B. Pullman. Reidel Publ. Comp. Dordrecht, Boston, London 1980, XVIII, 292 S., Zeichn. u. Tab., geb. $39, 50Nachrichten aus Chemie, Technik und Laboratorium, 1981